Astellas Pharma Financials
| ALPMF Stock | USD 10.37 0.12 1.17% |
Astellas |
Understanding current and past Astellas Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Astellas Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Astellas Pharma's assets may result in an increase in income on the income statement.
Astellas Pharma Stock Summary
Astellas Pharma competes with Sanofi ADR, Bristol Myers, AstraZeneca PLC, Gilead Sciences, and Novartis. Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 2-5-1, Nihonbashi-Honcho, Tokyo, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.astellas.com |
| Phone | 81 3 3244 3000 |
| Currency | USD - US Dollar |
Astellas Pharma Key Financial Ratios
There are many critical financial ratios that Astellas Pharma's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Astellas Pharma reports annually and quarterly.| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Target Price | 50.0 | |||
| Beta | 0.51 | |||
| Z Score | 3.0 |
Astellas Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Astellas Pharma's current stock value. Our valuation model uses many indicators to compare Astellas Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Astellas Pharma competition to find correlations between indicators driving Astellas Pharma's intrinsic value. More Info.Astellas Pharma is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Astellas Pharma is roughly 1.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Astellas Pharma's earnings, one of the primary drivers of an investment's value.Astellas Pharma Systematic Risk
Astellas Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Astellas Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Astellas Pharma correlated with the market. If Beta is less than 0 Astellas Pharma generally moves in the opposite direction as compared to the market. If Astellas Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Astellas Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Astellas Pharma is generally in the same direction as the market. If Beta > 1 Astellas Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Astellas Pharma December 13, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Astellas Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Astellas Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Astellas Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Astellas Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Astellas Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 20.76 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 5.72 |
Complementary Tools for Astellas Pink Sheet analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |